Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025

Rhea-AI Summary

Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company specializing in metabolic and endocrine disorder therapies, will release its Q2 2025 financial results on Wednesday, July 23, 2025, after market close.

The company will host a conference call at 4:30 p.m. Eastern Time to discuss financial results and provide corporate updates. Investors can join via phone or watch the webcast through Viking's website. A replay will be available until July 30, 2025, and the webcast recording will be accessible for 30 days.

News Market Reaction – VKTX

+1.39%

1 alert

+1.39% News Effect

+$49M Valuation Impact

$3.59B Market Cap

0.1x Rel. Volume

On the day this news was published, VKTX gained 1.39%, reflecting a mild positive market reaction. This price movement added approximately $49M to the company's valuation, bringing the market cap to $3.59B at that time.

Data tracked by StockTitan Argus on the day of publication.

 Conference Call Scheduled for Wednesday, July 23 at 4:30 p.m. Eastern Time          

SAN DIEGO, July 16, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the second quarter 2025 after the market close on Wednesday, July 23, 2025.

The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, July 23, 2025. To participate on the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until July 30, 2025, by dialing (877) 344-7529 from the U.S. or (412) 317-0088 from outside the U.S. and entering replay access code #4078954. Those interested in listening to the conference call live via the internet may do so by visiting the Webcasts page of Viking's website at http://ir.vikingtherapeutics.com/webcasts. An archive of the webcast will also be available on the Webcasts page of the company's website for 30 days.

About Viking Therapeutics, Inc.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is evaluating its subcutaneous formulation of VK2735 in a Phase 3 obesity program that includes two Phase 3 clinical trials (VANQUISH-1 and VANQUISH-2). Data from a Phase 1 and a Phase 2 trial evaluating subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 2 trial in obesity. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-second-quarter-2025-on-july-23-2025-302506053.html

SOURCE Viking Therapeutics, Inc.

FAQ

When will Viking Therapeutics (VKTX) report Q2 2025 earnings?

Viking Therapeutics will report Q2 2025 earnings on Wednesday, July 23, 2025, after the market close.

How can I listen to Viking Therapeutics Q2 2025 earnings call?

You can join the call by dialing (844) 850-0543 (U.S.) or (412) 317-5199 (international), or listen via webcast at Viking's investor relations website.

What time is Viking Therapeutics (VKTX) Q2 2025 earnings call?

The earnings conference call is scheduled for 4:30 p.m. Eastern Time on Wednesday, July 23, 2025.

How long will Viking Therapeutics Q2 2025 earnings call replay be available?

The telephone replay will be available until July 30, 2025, and the webcast recording will be accessible for 30 days on Viking's website.